Showing 3531-3540 of 5773 results for "".
- FDA Accepts Ocuphire's NDA for Nyxol Eye Drops for Reversal of Mydriasishttps://modernod.com/news/fda-accepts-ocuphires-new-drug-application-for-nyxol-eye-drops-for-reversal-of-mydriasis/2481404/Ocuphire Pharma announced that the FDA has accepted the new drug application (NDA) for Nyxol (phentolamine ophthalmic solution 0.75%) for the treatment of pharmacologically-induced mydriasis (RM). The FDA assigned a Prescription Drug User Fee Act (PDUFA) date of September 28, 2023.
- Allegro Ophthalmics Provides Updates on Dry AMD Pipeline Candidateshttps://modernod.com/news/allegro-ophthalmics-provides-updates-on-dry-amd-pipeline-candidates/2481403/Allegro Ophthalmics announced the presentation of data supporting dry AMD pipeline candidates, including risuteganib (Luminate), at the Bascom Palmer Eye Institute's 20th annual
- New Phase 3 Data Show Genentech’s Vabysmo Improved Vision and Reduced Retinal Fluid in People with RVOhttps://modernod.com/news/new-phase-3-data-show-genentechs-vabysmo-improved-vision-and-reduced-retinal-fluid-in-people-with-rvo/2481401/Genentech announced positive new data from two global phase 3 studies, BALATON and COMINO, evaluating Vabysmo (faricimab-svoa) in macular edema due to branch and central retinal vein occlusion (BRVO and CRVO) at 24 weeks. The studies showed that treatment with Vabysmo resulted in
- Radiance Therapeutics to Present at Glaucoma 360 New Horizons Forumhttps://modernod.com/news/radiance-therapeutics-to-present-at-glaucoma-360-new-horizons-forum/2481398/Radiance Therapeutics announced that Laurence Marsteller, MD, Chief Executive Officer, will present the company at the Glaucoma Research Foundation headline event, Glaucoma 360 New Horizons 2023, that will take place on February 3, 2023 in San Francisco. The Radiance Therapeut
- Novaliq Plans to File a Marketing Authorization Application for CyclASol in the EU for Dry Eye Diseasehttps://modernod.com/news/novaliq-plans-to-file-a-markting-authorization-application-for-cyclasol-in-the-eu-for-the-treatment-of-dry-eye-disease-in-july-2023/2481396/Novaliq announced its plans for filing a marketing authorization application (MAA) CyclASol (ciclosporin ophthalmic solution), a first-of-its-kind anti-inflammatory product for the treatment of dry eye disease (DED), in the European Union. The Committee for Medicinal Products for H
- Atsena Therapeutics to Present Positive Phase 1/2 Clinical Trial Data of ATSN-101 for the Treatment of GUCY2D-Associated LCA1https://modernod.com/news/atsena-therapeutics-to-present-positive-phase-12-clinical-trial-data-of-atsn-101-for-the-treatment-of-gucy2d-associated-lca1/2481394/Atsena Therapeutics announced that positive interim data from the ongoing phase 1/2 clinical trial of ATSN-101 will be presented at the 46th Annual Macula Society Meeting, which is being held February 15-18 in Miami. This is an encore presentation of data that were presented as a l
- Bausch + Lomb Launches Social Media Campaign Designed to Raise Awareness of AMDhttps://modernod.com/news/bausch-lomb-launches-social-media-campaign-designed-to-raise-awareness-of-amd/2481393/Bausch + Lomb announced a new social media campaign designed to raise awareness of age-related macular degeneration (AMD). The campaign, "What Sight Inspires You," will feature personal stories and sights from Bausch + Lomb’s SightMatters community, an online educat
- FDA Accepts NDA for Aldeyra's Reproxalap for the Treatment of Dry Eye Diseasehttps://modernod.com/news/fda-accepts-nda-for-aldeyras-reproxalap-for-the-treatment-of-dry-eye-disease/2481392/Aldeyra Therapeutics announced that the FDA has accepted the new drug application (NDA) for topical ocular reproxalap, a first-in-class investigational new drug candidate for the treatment of the signs and symptoms of dry eye disease. The FDA assigned a Prescription Drug User Fee A
- Omeros Receives $200 Million Milestone Payment from Raynerhttps://modernod.com/news/omeros-receives-200-million-milestone-payment-from-rayner/2481391/Omeros announced that Rayner has paid the $200 million milestone payment due to Omeros under the Asset Purchase Agreement, dated December 1, 2021, pursuant to which Omeros sold its ophthalmology product Omidria to Rayner in December of 2021. Omeros received
- Nidek Launches Cube Alpha Ophthalmic Surgical Systemhttps://modernod.com/news/nidek-launches-cube-a-ophthalmic-surgical-system/2481390/Nidek has announced the launch of the Cube α ophthalmic surgical system, which is designed to incorporate new ultrasound technology to deliver more powerful and effective phacoemulsification. According to Nidek, the Cube α incorporates Gyro torsional technolog